BRIEF published on 10/24/2026 at 13:05, 12 days 15 hours ago Nanobiotix Reports Final Phase 1 Results for NBTXR3 in Melanoma Clinical Trials Immunotherapy Melanoma NANOBIOTIX NBTXR3
PRESS RELEASE published on 10/24/2026 at 13:00, 12 days 15 hours ago NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma
BRIEF published on 10/20/2026 at 22:20, 16 days 6 hours ago Information on Nanobiotix Capital Voting Rights Euronext Actions Nasdaq NANOBIOTIX
BRIEF published on 10/20/2026 at 22:20, 16 days 6 hours ago Voting Rights and Shares Capital of NANOBIOTIX Voting Rights Euronext Nasdaq Shares Capital NANOBIOTIX
PRESS RELEASE published on 10/20/2026 at 22:15, 16 days 6 hours ago Voting Rights and Shares Capital of the Company Nanobiotix reports voting rights and shares capital. Company listed on Euronext Paris and Nasdaq. Focus on disruptive therapeutic approaches. Headquarters in Paris, France Euronext Paris Voting Rights Nasdaq Shares Capital NANOBIOTIX
BRIEF published on 10/01/2026 at 22:20, 1 month 4 days ago NANOBIOTIX Appoints Arnd Christ as CFO Biotechnology CFO Appointment Financial Leadership NANOBIOTIX Arnd Christ
BRIEF published on 10/01/2026 at 22:20, 1 month 4 days ago NANOBIOTIX appoints Arnd Christ as Chief Financial Officer Chief Financial Officer Biotechnology Appointment NANOBIOTIX Arnd Christ
PRESS RELEASE published on 10/01/2026 at 22:15, 1 month 4 days ago NANOBIOTIX Announces the Appointment of Arnd Christ as Chief Financial Officer Nanobiotix appoints Arnd Christ as CFO, bringing extensive financial leadership experience to advance treatment platforms for patients with cancer and major diseases CFO Cancer Treatment Financial Leadership NANOBIOTIX Arnd Christ
BRIEF published on 09/24/2026 at 22:20, 1 month 11 days ago NANOBIOTIX Reports First Half 2026 Operational and Financial Progress Cancer Treatment Financial Update NANOBIOTIX Phase 1 Study JNJ-1900 (NBTXR3)
PRESS RELEASE published on 09/24/2026 at 22:15, 1 month 11 days ago NANOBIOTIX Provides First Half 2026 Operational and Financial Update Nanobiotix provides operational and financial update for first half of 2026, showcasing progress in clinical development and successful global offering, reinforcing position in cancer treatment innovation Cancer Treatment Clinical Development Operational Update Financial Update NANOBIOTIX
Published on 11/06/2026 at 00:53, 4 hours 6 minutes ago Sekur Private Data Engages Darkstar Capital for Investor Awareness and Sekur Product Distribution
Published on 11/06/2026 at 00:45, 4 hours 14 minutes ago Gabriel Announces Closure of ICSID Annulment Proceedings
Published on 11/05/2026 at 23:20, 5 hours 39 minutes ago Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines
Published on 11/05/2026 at 22:05, 6 hours 54 minutes ago Innodata Reports Record Third Quarter 2026 Results
Published on 11/06/2026 at 04:15, 44 minutes ago Geely’s i-HEV Intelligent Hybrid Technology Offers a New Direction Vision for Gasoline-Powered Vehicles
Published on 11/06/2026 at 03:55, 1 hour 4 minutes ago Coway Announces Financial Results for Q3 FY2026
Published on 11/06/2026 at 00:05, 4 hours 54 minutes ago RBI: Announcement of the result of the voluntary public tender offer for all Addiko shares following expiration of the grace period
Published on 11/05/2026 at 22:05, 6 hours 54 minutes ago Quantinuum Reports Third Quarter 2026 Results and Raises Full-Year Revenue Outlook
Published on 11/05/2026 at 20:38, 8 hours 21 minutes ago freenet uses funds from Ceconomy sale for waipu.tv acquisition and share buyback
Published on 11/05/2026 at 18:21, 10 hours 37 minutes ago Total number of voting rights and shares making up the share capital at October 31, 2026
Published on 11/05/2026 at 17:45, 11 hours 14 minutes ago MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 11/05/2026 at 17:29, 11 hours 30 minutes ago Notice of exercise of early redemption option of the subordinated note ISIN FR0010406082
Published on 11/05/2026 at 10:16, 18 hours 43 minutes ago Growth acceleration confirmed in the third quarter of 2026 All businesses growing, revenue up +6,5%
